<p>至少有六家生物技术公司专注于迷幻药，在白宫发布旨在鼓励这些药物用于心理健康的行政命令后，其股票上涨。</p>
<p>该命令于周六发布，指示食品药品监督管理局局长为 FDA 已将其分类为潜在突破性治疗的 “适当” 迷幻药提供一种新的——且有争议的——代金券。这一分类以及 “国家优先代金券” 旨在显著加快某些疗法的开发和监管审查。</p>
<p>此外，特朗普政府希望 FDA 和药物执法局协助建立一条途径，使符合条件的患者能够根据《尝试权法》获得迷幻药物。其他条款包括指示卫生与公共服务部与州政府和退伍军人事务部合作，推进迷幻药物的研究和测试。</p>
<p>“我的政府的政策是加速创新研究模型和适当的药物批准，以增加对可能拯救生命并逆转美国严重心理疾病危机的迷幻药物的获取，” 特朗普总统写道。</p>
<p>该命令特别提到了一种在中非原生灌木中发现的迷幻化合物——伊博加因。但在华尔街，分析师们普遍认为这一命令是对迷幻药开发者的重大胜利。杰富瑞的安德鲁·蔡称其为 “对这一类别的官方认可印章”，并证明白宫和这些机构计划以 “真实” 和 “可操作” 的方式支持迷幻药物。</p>
<p>几家开发者的股票随后上涨了高个位数或更多。其中一家，Enveric Biosciences，几乎翻了三倍。这家位于马萨诸塞州剑桥的生物技术公司正在开发一种与一种被称为 “DMT” 的迷幻化合物类似的药物。它旨在通过与两种调节血清素的蛋白质相互作用，重新连接大脑电路，从而影响情绪、情感和认知。</p>
<h6>选定迷幻药开发者的股票变动</h6>
<table>
<thead>
<tr>
<th>公司</th>
<th>股票代码</th>
<th>周五收盘</th>
<th>周一最高</th>
<th>百分比变化</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helus Pharma</td>
<td>HELP</td>
<td>$5.50</td>
<td>$6.00</td>
<td>9%</td>
</tr>
<tr>
<td>Definium Therapeutics</td>
<td>DFTX</td>
<td>$22.68</td>
<td>$26.25</td>
<td>16%</td>
</tr>
<tr>
<td>GH Research</td>
<td>GHRS</td>
<td>$18.34</td>
<td>$24.66</td>
<td>34%</td>
</tr>
<tr>
<td>AtaiBeckley</td>
<td>ATAI</td>
<td>$4.03</td>
<td>$5.50</td>
<td>36%</td>
</tr>
<tr>
<td>Compass Pathways</td>
<td>COMP</td>
<td>$6.66</td>
<td>$10.21</td>
<td>53%</td>
</tr>
<tr>
<td>Enveric Biosciences</td>
<td>ENVB</td>
<td>$1.82</td>
<td>$5.43</td>
<td>198%</td>
</tr>
</tbody>
</table>
<p>来源：雅虎财经数据</p>
<p>根据 RBC 资本市场的分析师布赖恩·阿布拉罕斯的说法，该命令中两个最直接受益的部分是针对突破性药物的国家优先代金券和 DEA 指令，要求在批准后迅速重新分类迷幻药物。这两个要素 “应该能缩短 FDA 审查和可及性的额外几个月，并加速潜在的收入生成，” 阿布拉罕斯在给客户的报告中写道。</p>
<p>在他自己的报告中，Stifel 的保罗·马特斯写道，FDA 专员马丁·马卡里表示，三种针对特定血清素受体的迷幻药可能会在本周获得代金券。</p>
<p>根据马特斯的说法，两个最明显的潜在受益者是 Compass Pathways 和 Definium Therapeutics。Compass 在两项晚期研究中获得了 “COMP360” 的积极数据，这是一种合成的迷幻药，正朝着成为美国市场上首个获得批准的 “经典” 迷幻药的方向发展。与此同时，Definium（前身为 MindMed）有一种合成的 LSD 衍生物，已进入第三阶段测试，作为治疗重度抑郁症和广泛性焦虑症的可能疗法。</p>
<p>第三个代金券的潜在受益者尚不明确，但总体而言，“这对该领域是一个顺风”，马特斯写道。</p>
<p>分析师们一致认为，该命令有助于降低一个研究领域的风险，过去几年中一些投资者对此变得更加谨慎。推动这种怀疑的因素包括 FDA 拒绝 MDMA 辅助治疗 PTSD，以及 Stat News 的报告称 COMP360 曾被阻止纳入该机构的代金券名单。</p>
<p>杰富瑞的蔡强调了其他最近的发展，这些发展有助于改善对迷幻药物的情绪。FDA 和 HHS 的高级官员，如马卡里和罗伯特·F·肯尼迪 Jr.，已表达对这些类型药物的支持。该领域还受益于一些交易——如大冢制药与 Transcend Therapeutics 之间的交易，以及 AbbVie 与 Gilgamesh Pharmaceuticals 之间的交易——以及强生的氟氯噻吨（Spravato）这一源自氟噻吨的抑郁症疗法的商业成功。</p>
<p>“总的来说：这些因素的汇聚使我们相信迷幻药物是一个值得投资的领域，” 蔡写道。</p>

ENVB

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

PSIL

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

<p>特朗普总统的一项行政命令导致专注于迷幻药的生物技术公司股票激增，因为该命令旨在加快这些药物在心理健康领域的开发。该命令包括 FDA 发放突破性迷幻药物国家优先券的条款，并促进患者根据《尝试权法》获得药物的机会。分析师认为，这对迷幻药行业是一个重要的推动，像 Enveric Biosciences 这样的公司股票上涨近 200%。总体而言，该命令预计将加快 FDA 的审查进程，并增强这些公司的收入潜力</p>

<p>At least half a dozen biotechnology companies working on psychedelics saw their stocks rise following an executive order from the White House meant to encourage the development of these drugs for mental health.</p>
<div class="lb-trans"><p>至少有六家生物技术公司专注于迷幻药，在白宫发布旨在鼓励这些药物用于心理健康的行政命令后，其股票上涨。</p>
</div><p>The order, issued Saturday, directs the head of the Food and Drug Administration to provide a new — and controversial — kind of voucher to “appropriate” psychedelic medicines that the FDA has classified as potential breakthroughs for serious conditions. That classification, as well as the “national priority vouchers,” are designed to significantly speed up the development and regulatory review of certain therapies.</p>
<div class="lb-trans"><p>该命令于周六发布，指示食品药品监督管理局局长为 FDA 已将其分类为潜在突破性治疗的 “适当” 迷幻药提供一种新的——且有争议的——代金券。这一分类以及 “国家优先代金券” 旨在显著加快某些疗法的开发和监管审查。</p>
</div><p>Additionally, the Trump administration wants the FDA and the Drug Enforcement Administration to assist in setting up a pathway for eligible patients to get ahold of psychedelic medicines under the Right to Try Act. Other provisions include instructions for the Department of Health and Human Services to collaborate with state governments and the Department of Veterans Affairs to advance the research and testing of psychedelics.</p>
<div class="lb-trans"><p>此外，特朗普政府希望 FDA 和药物执法局协助建立一条途径，使符合条件的患者能够根据《尝试权法》获得迷幻药物。其他条款包括指示卫生与公共服务部与州政府和退伍军人事务部合作，推进迷幻药物的研究和测试。</p>
</div><p>“It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America,” President Trump wrote.</p>
<div class="lb-trans"><p>“我的政府的政策是加速创新研究模型和适当的药物批准，以增加对可能拯救生命并逆转美国严重心理疾病危机的迷幻药物的获取，” 特朗普总统写道。</p>
</div><p>The order specially mentions ibogaine, a psychoactive compound found in shrubs native to central Africa. But on Wall Street, analysts view the mandate as a major win for psychedelics developers broadly. Andrew Tsai, of Jefferies, called it “an official stamp of validation to the class” and evidence that the White House and these agencies plan to support psychedelics in “real” and “actionable” ways.</p>
<div class="lb-trans"><p>该命令特别提到了一种在中非原生灌木中发现的迷幻化合物——伊博加因。但在华尔街，分析师们普遍认为这一命令是对迷幻药开发者的重大胜利。杰富瑞的安德鲁·蔡称其为 “对这一类别的官方认可印章”，并证明白宫和这些机构计划以 “真实” 和 “可操作” 的方式支持迷幻药物。</p>
</div><p>Shares of several developers subsequently spiked by high single-digits or more. One, Enveric Biosciences, nearly tripled. The Cambridge, Massachusetts-based biotech is working on an analog to a hallucinogenic compound known as “DMT.” It’s supposed to rewire brain circuitry by interacting with two kinds of proteins that regulate serotonin and, by extension, affect mood, emotions and cognition.</p>
<div class="lb-trans"><p>几家开发者的股票随后上涨了高个位数或更多。其中一家，Enveric Biosciences，几乎翻了三倍。这家位于马萨诸塞州剑桥的生物技术公司正在开发一种与一种被称为 “DMT” 的迷幻化合物类似的药物。它旨在通过与两种调节血清素的蛋白质相互作用，重新连接大脑电路，从而影响情绪、情感和认知。</p>
</div><h6>Stock changes of select psychedelics developers</h6>
<div class="lb-trans"><h6>选定迷幻药开发者的股票变动</h6>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Friday close</th>
<th>Monday High</th>
<th>Percent change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helus Pharma</td>
<td>HELP</td>
<td>$5.50</td>
<td>$6.00</td>
<td>9%</td>
</tr>
<tr>
<td>Definium Therapeutics</td>
<td>DFTX</td>
<td>$22.68</td>
<td>$26.25</td>
<td>16%</td>
</tr>
<tr>
<td>GH Research</td>
<td>GHRS</td>
<td>$18.34</td>
<td>$24.66</td>
<td>34%</td>
</tr>
<tr>
<td>AtaiBeckley</td>
<td>ATAI</td>
<td>$4.03</td>
<td>$5.50</td>
<td>36%</td>
</tr>
<tr>
<td>Compass Pathways</td>
<td>COMP</td>
<td>$6.66</td>
<td>$10.21</td>
<td>53%</td>
</tr>
<tr>
<td>Enveric Biosciences</td>
<td>ENVB</td>
<td>$1.82</td>
<td>$5.43</td>
<td>198%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>股票代码</th>
<th>周五收盘</th>
<th>周一最高</th>
<th>百分比变化</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helus Pharma</td>
<td>HELP</td>
<td>$5.50</td>
<td>$6.00</td>
<td>9%</td>
</tr>
<tr>
<td>Definium Therapeutics</td>
<td>DFTX</td>
<td>$22.68</td>
<td>$26.25</td>
<td>16%</td>
</tr>
<tr>
<td>GH Research</td>
<td>GHRS</td>
<td>$18.34</td>
<td>$24.66</td>
<td>34%</td>
</tr>
<tr>
<td>AtaiBeckley</td>
<td>ATAI</td>
<td>$4.03</td>
<td>$5.50</td>
<td>36%</td>
</tr>
<tr>
<td>Compass Pathways</td>
<td>COMP</td>
<td>$6.66</td>
<td>$10.21</td>
<td>53%</td>
</tr>
<tr>
<td>Enveric Biosciences</td>
<td>ENVB</td>
<td>$1.82</td>
<td>$5.43</td>
<td>198%</td>
</tr>
</tbody>
</table>
</div><p>SOURCE: Yahoo Finance data</p>
<div class="lb-trans"><p>来源：雅虎财经数据</p>
</div><p>To Brian Abrahams, an analyst at RBC Capital Markets, the two most directly beneficial pieces of the order are the national priority vouchers for drugs with breakthrough designation and the DEA directive to quickly reschedule psychedelic drugs post-approval. Both of those elements “should shave additional months off of FDA review and accessibility and accelerate potential revenue generation,” Abrahams wrote in a note to clients.</p>
<div class="lb-trans"><p>根据 RBC 资本市场的分析师布赖恩·阿布拉罕斯的说法，该命令中两个最直接受益的部分是针对突破性药物的国家优先代金券和 DEA 指令，要求在批准后迅速重新分类迷幻药物。这两个要素 “应该能缩短 FDA 审查和可及性的额外几个月，并加速潜在的收入生成，” 阿布拉罕斯在给客户的报告中写道。</p>
</div><p>In his own note, Stifel’s Paul Matteis wrote that FDA Commissioner Martin Makary said three psychedelics that go after a particular serotonin receptor may receive a voucher this week.</p>
<div class="lb-trans"><p>在他自己的报告中，Stifel 的保罗·马特斯写道，FDA 专员马丁·马卡里表示，三种针对特定血清素受体的迷幻药可能会在本周获得代金券。</p>
</div><p>The two most obvious potential recipients, according to Matteis, are Compass Pathways and Definium Therapeutics. Compass has scored positive data in two late-stage studies for “COMP360,” a synthetic form of psilocybin that’s on track to becoming the first “classic” psychedelic cleared for the U.S. market. Meanwhile, Definium, formerly named MindMed, has a synthetic derivative of LSD that’s progressed to Phase 3 testing as a possible treatment for major depressive disorder and generalized anxiety disorder.</p>
<div class="lb-trans"><p>根据马特斯的说法，两个最明显的潜在受益者是 Compass Pathways 和 Definium Therapeutics。Compass 在两项晚期研究中获得了 “COMP360” 的积极数据，这是一种合成的迷幻药，正朝着成为美国市场上首个获得批准的 “经典” 迷幻药的方向发展。与此同时，Definium（前身为 MindMed）有一种合成的 LSD 衍生物，已进入第三阶段测试，作为治疗重度抑郁症和广泛性焦虑症的可能疗法。</p>
</div><p>Who the third voucher might go to is less clear, but overall “this is a tailwind for the space,” Matteis wrote.</p>
<div class="lb-trans"><p>第三个代金券的潜在受益者尚不明确，但总体而言，“这对该领域是一个顺风”，马特斯写道。</p>
</div><p>Analysts agreed the order helps de-risk a research area that at least some investors had grown more wary of over the past couple years. Fueling that skepticism was the FDA’s rejection of MDMA-assisted therapy for PTSD, and a report from Stat News that COMP360 had previously been blocked from inclusion on the agency’s voucher list.</p>
<div class="lb-trans"><p>分析师们一致认为，该命令有助于降低一个研究领域的风险，过去几年中一些投资者对此变得更加谨慎。推动这种怀疑的因素包括 FDA 拒绝 MDMA 辅助治疗 PTSD，以及 Stat News 的报告称 COMP360 曾被阻止纳入该机构的代金券名单。</p>
</div><p>Tsai, of Jefferies, highlighted other recent developments that have helped improve the sentiment around psychedelics. Top officials at the FDA and HHS, like Makary and Robert F. Kennedy Jr., have voiced support for these types of drugs. The field has also benefited from deals — like those between Otsuka Pharmaceutical and Transcend Therapeutics and AbbVie and Gilgamesh Pharmaceuticals — as well as the commercial success of Spravato, a ketamine-derived depression therapy from Johnson &amp; Johnson.</p>
<div class="lb-trans"><p>杰富瑞的蔡强调了其他最近的发展，这些发展有助于改善对迷幻药物的情绪。FDA 和 HHS 的高级官员，如马卡里和罗伯特·F·肯尼迪 Jr.，已表达对这些类型药物的支持。该领域还受益于一些交易——如大冢制药与 Transcend Therapeutics 之间的交易，以及 AbbVie 与 Gilgamesh Pharmaceuticals 之间的交易——以及强生的氟氯噻吨（Spravato）这一源自氟噻吨的抑郁症疗法的商业成功。</p>
</div><p>“Net-net: The culmination of these factors makes us believe psychedelics are an investable space,” Tsai wrote.</p>
<div class="lb-trans"><p>“总的来说：这些因素的汇聚使我们相信迷幻药物是一个值得投资的领域，” 蔡写道。</p>
</div>

特朗普的行政命令提振了迷幻药生物技术公司